Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma |
| Completed | 3 | 51 | US | NewGam, Human normal immunoglobulin | Octapharma, Premier Research Group plc | Primary Immunodeficiency Diseases | 06/12 | 06/12 | | |
| Completed | 3 | 21 | US | NewGam | Octapharma | Primary Immunodeficiency Disease | 09/12 | 09/12 | | |
| Completed | 3 | 40 | Europe | NewGam | Octapharma | Primary Thrombocytopenia | 07/13 | 07/13 | | |
NCT02638207 / 2015-005443-14: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy |
|
|
| Completed | 3 | 142 | Europe, Canada, RoW | NewGam, Panzyga | Octapharma | Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | 09/19 | 09/19 | | |
2019-004375-40: Study for the evaluatiion of Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study) Studie zur Ermittlung der Wirksamkeit und Sicherheit von Panzyga in der primären Infektionsprophylaxe bei Patienten mit chronischer lymphatischer Leukämie ("PRO-SID"-Studie) |
|
|
| Not yet recruiting | 3 | 450 | Europe, RoW | Panzyga, [NA], Solution for infusion, Panzyga | Octapharma Pharmazeutika Produktionsges.m.b.H., OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H., Octapharma Pharmazeutika Produktionsges.m.b.H. | Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia, Prophylaxis to prevent infection in patients with a type of cancer that starts in bone marrow and then go into the blood, Diseases [C] - Cancer [C04] | | | | |
PROSID, NCT04502030: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) |
|
|
| Recruiting | 3 | 240 | Europe, US, RoW | Panzyga, Placebo | Octapharma | Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | 10/25 | 10/25 | | |
| Active, not recruiting | 3 | 70 | Europe, US | Panzyga, Placebo | Octapharma | Pediatric Acute-Onset Neuropsychiatric Syndrome | 06/24 | 06/24 | | |
NGAM-11, NCT04929236 / 2021-003200-40: Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients |
|
|
| Recruiting | 3 | 30 | US | Panzyga | Octapharma | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | 06/26 | 06/26 | | |
| Terminated | 2/3 | 2 | NA | NewGam 10%, Placebo, 0.9% saline solution | Octapharma | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 10/12 | 10/12 | | |